Tirzepatide Reduced the Risk of Developing Type 2 Diabetes by 94% in Adults with Pre-Diabetes and Obesity or Overweight
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight, and resulted in sustained weight loss over a three-year treatment period.
Related Clinical Trials
Highlighted Terms
Related News
Once-weekly tirzepatide outperforms daily insulin in reducing blood sugar, weight, and cardiovascular risks in type 2 diabetes management, according to a meta-analysis of over 4,300 patients.
Tirzepatide, in Zepbound, reduced type 2 diabetes risk by 94% in obese or overweight adults with pre-diabetes, with sustained weight loss. Potential side effects include stomach and kidney issues, low blood sugar, and allergic reactions. Long-term effectiveness remains uncertain.
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight, and resulted in sustained weight loss over a three-year treatment period.